Start the conversation
You see, Organovo Holdings Inc. (NYSEMKT: ONVO) is part of one of the most exciting biotech industries on the market. It's called 3D bioprinting, and the applications are huge.
Here's a closer look at the 3D bioprinting market and why it's providing us with such a great investment opportunity.
Organovo Stock and the Potential of 3D Bioprinting
Bioprinting refers to Organovo's process of developing functional human tissues that are used in drug development, biological research, and as therapeutic implants for degenerating tissues and organs.
"Organovo makes the tissue with an exciting new technology called 3D Bioprinting, which identifies key architectural and compositional elements of a target tissue," Money Morning Bioscience Investing Specialist Ernie Tremblay said. "It then creates a design that can be utilized by a 'bioprinter' to generate that tissue in the laboratory."
This allows doctors and researchers to provide "personalized medicine" to their patients. Instead of a "one-size-fits-all" treatment for thousands of patients, these work differently for every patient based on his or her needs.
"The idea is simply this: with current technologies, it's possible to design drugs, such as cell therapy products, that can be altered or optimally combined to fit the genetic and morphological profile of each individual patient, often recruiting his or her own immune system into the fight," Tremblay said.
"Personalized medicine could provide real-life 'magic bullets' for diseases like cancer, multiple sclerosis, lupus, and inflammatory bowel disease (Crohn's and ulcerative colitis)," he continued.
And the applications stretch far beyond diseases.
"This field also holds the promise of miraculous treatments for severe spinal injuries, joint and bone repair, and organ replacement," Tremblay said.
There is some serious money flowing into personalized medicine, too. According to the Alliance of Regenerative and Personalized Medicine, cell therapies have already generated $900 million in revenue. At the end of 2014, more than 160,000 patients had received treatment.